Apaxen is a privately-held biotechnology company whose mission is to bring innovative treatments to patients in a wide range of therapeutic indications related to chronic inflammation, with a primary focus in pulmonary arterial hypertension (PAH) and other deadly pulmonary diseases.
The Company is specialized in the discovery and development of first-in-class small molecule inhibitors of pleiotropic pro-inflammatory cytokine “Macrophage migration Inhibitory Factor (MIF)”, a crucial regulator of innate immune responses. Apaxen’s lead compound, MFC-1040, an orally bioavailable and selective small molecule MIF inhibitor, is being developed for the treatment of pulmonary arterial hypertension (PAH), a rare and fatal disease, with a strong medical need since approved treatments are symptomatic and associated with low median survival.
MFC-1040 has a unique mechanism of action and has the potential to revolutionize the standard of care of PAH and other diseases related to chronic inflammation.
Apaxen has its headquarters in Gosselies, at the Biopark Charleroi Brussels South
Company Details
- Founded
- -
- Address
- Rue Auguste Piccard 48, Charleroi,walloon Region 6041,belgium
- Industry
- Biotechnology
- Keywords
- Groningen.
- HQ
- Charleroi, Walloon Region
Apaxen Questions
Apaxen's LinkedIn profile is https://be.linkedin.com/company/apaxen
Apaxen's industry is
Biotechnology
Apaxen's top competitors are
Neuvasq Biotechnologies,
Eurobiobmd,
Am-Biotech Consulting,
Hussard Rh,
Leader Biomedical Europe B.v.,
Biowin Days,
A-Ulab,
Lanthio Pharma,
Biomedical Diagnostics Institute,
Glycotreat.
Apaxen's categories are Biotechnology
Apaxen's founding year is 2018
